Clinical evaluation of iodine-125 brachytherapy in hilar cholangiocarcinoma

VernacularTitle:125I粒子可更换持续照射系统治疗不可切除肝门部胆管癌
Author: Lei ZOU ; Yan JIN ; Ou QIAO ; Xiufang ZHU ; Yiwo MO
Publication Type:Journal Article
Keywords: Hilar cholangiocarcinoma; New treatments; Iodine 125 seeds; Brachytherapy
From: Chinese Journal of Hepatobiliary Surgery 2015;21(6):418-420
CountryChina
Language:Chinese
Abstract: Hilar cholangiocarcinoma is a common bile duct cancer.The radical resection rate of end-stage malignancies reported in literature is about 20％.Half of the patients have lost the chance of operation at the time of care,while the average survival time in the patients who can not be operated is about six months.Therefore,for most patients,looking for a palliative treatment which can prolong the survival time is particularly important.From June 2013 to June 2014,our hospital applied iodine-125 brachytherapy,to treat 7 patients with unresectable hilar cholangio carcinoma.All the patients are still alive,the average survival time of 7 patients is 5.2 months up to now,with median survival time being 7.8 months,and longest survival time being 12 months.With good outcomes,few complications,as well as significantly prolonged survival time,iodine125 brachytherapy is regarded with broad clinical applications.